German startup company Miraculix has launched rapid analysis mobile kits to measure the concentration of psilocybin, LSD & MDMA in samples.

The findings of this study suggest that ayahuasca promotes well-being and self-compassion.

After languishing for decades from legal restrictions and stigma, research into psychedelic drugs is exploding – with the encouragement of the Food and Drug Administration. Recent clinical trial successes suggest some long-banned drugs could soon be authorized as treatments for debilitating illnesses.

There is a growing body of evidence suggesting that the psychedelic plant tea, ayahuasca, holds therapeutic potential. The present study aimed to replicate and extend these findings.

Spontaneous spiritual awakenings: phenomenology, altered states, individual differences, and well-being

Serotonin toxicity of serotonergic psychedelics

Pharmacologic similarities and differences among hallucinogens

Lysergic acid diethylamide, psilocybin and dimethyltryptamine in depression treatment

potential synergistic effects between mindfulness training and psychedelic-assisted therapy

Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color

Canadian advocacy group 'TheraPsil' push to legalize therapeutic psilocybin

Two models of legalization of psychedelic substances

Cancer healthcare workers’ perceptions toward psychedelic-assisted therapy

Recreation and realization: Reported motivations of use among persons who consume psychedelics in non-clinical settings

psychotherapeutic components of psilocybin-assisted psychotherapy

Ketamine for bipolar depression

Pharmacodynamic interactions between ketamine and psychiatric medications

Does psychedelic therapy have a transdiagnostic action